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Abstract
Aspirin prevents thrombosis by inhibiting platelet cyclooxygenase (COX)-1 activity 
and the production of thromboxane (Tx)A2, a pro-thrombotic eicosanoid. However, 
the non-platelet actions of aspirin limit its antithrombotic effects. Here, we used 
platelet-COX-1-ko mice to define the platelet and non-platelet eicosanoids affected 
by aspirin. Mass-spectrometry analysis demonstrated blood from platelet-COX-1-ko 
and global-COX-1-ko mice produced similar eicosanoid profiles in vitro: for ex-
ample, formation of TxA2, prostaglandin (PG) F2α, 11-hydroxyeicosatraenoic acid 
(HETE), and 15-HETE was absent in both platelet- and global-COX-1-ko mice. 
Conversely, in vivo, platelet-COX-1-ko mice had a distinctly different profile from 
global-COX-1-ko or aspirin-treated control mice, notably significantly higher levels 
of PGI2 metabolite. Ingenuity Pathway Analysis (IPA) predicted that platelet-COX-
1-ko mice would be protected from thrombosis, forming less pro-thrombotic TxA2 
and PGE2. Conversely, aspirin or lack of systemic COX-1 activity decreased the 
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1 |  INTRODUCTION
Cardiovascular diseases are the leading cause of death and 
disability worldwide.1 They are associated with the forma-
tion of arterial thrombi following excessive platelet activation 
and aggregation at disrupted vascular sites resulting in acute 
vessel occlusion and ischemic events.2,3 Aspirin has been the 
cornerstone of antiplatelet therapy for more than three de-
cades, with numerous trials demonstrating that low doses 
of aspirin reduce the incidence of secondary cardiovascular 
events.4-6 Recent studies have, however, raised doubts as to 
whether the previously observed benefits of aspirin in sec-
ondary prevention are maintained under current clinical care 
regimes where aspirin is often given together with a P2Y12 
receptor antagonist, such as prasugrel or ticagrelor. For ex-
ample, the platelet inhibition and patient outcomes (PLATO) 
trial reported an association between higher doses of aspirin 
and increased thrombotic risk in individuals taking ticagre-
lor.7 Newer studies are therefore evaluating the benefits of 
low- vs high-dose aspirin in patients who have had previous 
cardiovascular events8 and whether aspirin discontinuation in 
favor of single drug therapy with a P2Y12 receptor antagonist 
could retain antithrombotic efficacy.9,10 The first results of 
these trials indicate that low-dose aspirin does not increase the 
protection from ischemic events afforded by ticagrelor.11,12
The platelet inhibitory effects of aspirin are explained by its 
ability to irreversibly inhibit cyclooxygenase (COX)-1 in plate-
lets, and therefore, the conversion of AA to thromboxane (Tx)
A2, an eicosanoid that promotes platelet aggregation and throm-
bosis.13,14 Importantly, platelet COX-1 also supports the pro-
duction of other eicosanoids, including prostaglandins (PGs) 
such as PGE2, PGD2, PGF2,
15,16 and 11- and 15- hydroxye-
icosatraenoic acid (HETE),17-19 which have mixed actions on 
platelet activation, vascular function, and thrombosis.20-27
It has been hypothesized that the antiplatelet effect of aspi-
rin mediated by inhibition of TxA2 is counterbalanced by as-
pirin inhibition of COX-1 and possibly COX-2 at non-platelet 
sites that reduces the synthesis of vasorelaxant and anti-ag-
gregatory mediators such as PGI2.
28-30 However, the com-
plete profile of eicosanoids whose synthesis is affected by 
the action of aspirin on platelet COX-1 and on other tissues 
and how it relates to the anti- and pro-thrombotic effects of 
aspirin has been so far poorly characterized.
This has been difficult to appreciate because the pharma-
cokinetics and pharmacodynamics of aspirin are substantially 
different in mice and humans. Mice, in fact, require two hun-
dred fold higher oral dose of aspirin than humans to achieve 
complete suppression of platelet COX-1 activity,31,32 but this 
dose of aspirin unavoidably affects COX activity in different 
body compartments.
While mice with global COX-1 knockout (COX-1−/−; 
hereafter, global-COX-1-ko mice) have been available for 
some time,33 selective COX-1 cell-type deletion has only 
very recently been documented.34,35
Here, we used mice with selective deletion of platelet 
COX-1 to mimic the selective effect of aspirin on platelet 
COX-1 eicosanoid synthesis. We compared this eicosanoid 
profile to those obtained in global-COX-1-ko mice, with lack 
of COX-1 activity in the entire body, and in mice treated with 
high-dose aspirin to achieve COX enzyme inhibition in platelet 
and non-platelet targets. We described that aspirin affects dif-
ferent networks of AA-derived eicosanoids dependent upon its 
action on platelet COX-1 or on non-platelet COX targets. By 
interrogating Ingenuity Pathway Analysis (IPA), we found that 
loss of COX-1-related eicosanoids in platelets is antithrom-
botic, but loss of COX-1- and, possibly, COX-2-related eico-
sanoids in the remaining of the cardiovascular system limits 
aspirin’s antithrombotic effects. These findings were validated 
by assessing platelet aggregation in vitro and thrombus forma-
tion in vivo. These results could offer a mechanistic explana-
tion as to why the addition of aspirin to other antithrombotic 
drugs or increase in aspirin dose does not add antithrombotic 
benefit for human subjects and may increase thrombotic risk.
2 |  MATERIALS AND METHODS
2.1 | Mice
We used a Cre/loxP system to create transgenic mice 
with deletion of COX-1 in platelets. Floxed COX-1 mice 
(Ptgs1flox/flox mice) were generated by flanking exons 3 and 
synthesis of anti-aggregatory PGI2 and PGD2 at non-platelet sites leading to predicted 
thrombosis increase. In vitro and in vivo thrombosis studies proved these predictions. 
Overall, we have established the eicosanoid profiles linked to inhibition of COX-1 in 
platelets and in the remainder of the cardiovascular system and linked them to anti- 
and pro-thrombotic effects of aspirin. These results explain why increasing aspirin 
dosage or aspirin addition to other drugs may lessen antithrombotic protection.
K E Y W O R D S
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5 of the COX-1 gene with lox P sites in ES cells, which 
were injected into blastocysts to create chimeric mice with 
germline transmission. These animals have been depos-
ited at Jackson Laboratories (USA) as strain no. 030884. 
COX-1fl/fl mice were then crossed with Pf4Cre mice (pro-
vided by Prof Steve Watson, University of Birmingham, 
United Kingdom, and used with the permission of Prof. 
Radek Skoda, University of Basel, Switzerland) to specifi-
cally delete COX-1 in the megakaryocyte lineage (Ptgs1flox/
flox;Pf4Cre). Ptgs1flox/flox;Pf4Cre mice were mated with 
Ptgs1flox/flox mice to produce Ptgs1flox/flox;Pf4Cre mice 
(platelet-COX-1-ko mice) and Ptgs1flox/flox  littermate con-
trols (hereafter control mice). This strain was maintained 
on a mixed C57Bl/6 and 129S4/SvJae background. Global-
COX-1-ko mice on a C57BL/6 background were generated 
as previously described.33
Animals were housed with free access to food (RM1; 
Special Diet Services, UK) and water under a 12 hours day/
night cycle. Eight- to 12-week old mice were used for all ex-
periments and all procedures described in this study were sub-
ject to UK Home Office approval (PPL 70/8422) under “The 
Animals (Scientific Procedures) Act (1986) Amendment 
Regulations (2012)” following review by the Queen Mary 
University and Imperial College Animal Welfare and Ethical 
Review Board. Animals were randomized through allocation 
of sequential number at weaning (prior to genotyping) and 
experiments performed in this order.
2.2 | Complete blood counts and platelet 
preparation
Mice were anesthetized with intraperitoneal (i.p.) keta-
mine (Narketan, 100 mg/kg; Vetoquinol, UK) and xylazine 
(Rompun, 10 mg/kg; Bayer, Germany) and blood was col-
lected from the inferior vena cava. Complete blood counts 
were performed on blood collected in EDTA (IDEXX 
BioResearch, Germany). To prepare platelet-rich plasma 
(PRP) blood was anticoagulated with sodium citrate (0.32%; 
Sigma, UK), diluted 1:1 in modified Tyrode’s HEPES (MTH) 
buffer (containing 134 mmol/L NaCl, 2.9 mmol/L KCl, 0.34 
mmol/L Na2HPO4, 12 mmol/L NaHCO3, 1 mmol/L MgCl2, 
and 20 mmol/L HEPES, pH 7.4; all Sigma, UK) and centri-
fuged at 100 g for 8 minutes, followed by centrifugation of 
the supernatant and the buffy coat at 100 g for 6 minutes. 
The PRP was then used for immunofluorescence studies or to 
isolate platelets for immunoblot analysis. For the latter pur-
pose, PRP was further centrifuged (750 g, 10 minutes) in the 
presence of PGI2 (PGI2, 1 μg/mL; Tocris Bioscience, UK) 
and apyrase (0.02 U/mL; Sigma, UK). The resulting platelet 
pellet was washed in MTH buffer containing 0.02 U/mL of 
apyrase (Sigma, UK) and resuspended to a final concentra-
tion of 1 × 109 platelets/mL in MTH buffer.
2.3 | Immunoblot analysis
1 × 109 platelets/mL (final) were resuspended in MTH buffer 
pH 7.4 containing protease inhibitor cocktail (5 mmol/L 
EDTA; Complete; Roche Diagnostics, Sigma, UK) and lysed 
by the addition of Triton X-100 (0.5% v/v). Alternatively, snap-
frozen tissues were homogenized in phosphate-buffered saline 
(PBS) containing EDTA (10 mmol/L), Triton-X 100 (1%), 
phenylmethylsulfonyl fluoride (1 mmol/L), and protease in-
hibitor mixture (1×) using a Precellys 24 homogenizer (Bertin 
Instruments, France). SDS-PAGE and immunoblotting of cell 
lysates were performed using standard protocols. Membranes 
were probed with primary antibodies against mouse COX-1 
(rabbit anti-mouse polyclonal IgG; Cell Signaling Technology, 
New England BioLabs, UK; catalogue no. 4841S; 1:1000) and 
GAPDH (rabbit anti-mouse monoclonal IgG; Cell Signaling 
Technology, New England BioLabs, UK; catalogue no. 
5174S; 1:10 000) followed by secondary horseradish perox-
idase-conjugated goat anti-rabbit IgG antibody (Sigma, UK; 
catalogue no. 12-348; 1:10 000). Proteins were detected by en-
hanced chemiluminescence reaction (BioRad GE Healthcare, 
UK) using clear-blue X-ray film or an ImageQuant-RT ECL 
imaging system (GE Healthcare, UK).
2.4 | Immunostaining and Airyscan laser 
scanning confocal microscopy
For platelet imaging the PRP was mixed with equal volumes 
of 8% paraformaldehyde in PBS and platelets were left to 
fix for 15 minutes at room temperature.36 Platelets were pel-
leted by centrifugation at 1000 g for 10 minutes, washed with 
PBS, and resuspended in PBS plus 1% BSA. To image the 
mixed population of platelets and leukocytes, the buffy coat 
was isolated from the PRP and treated with Lyse/Fix solu-
tion (BD Bioscience, Germany) to break the erythrocytes and 
fix the rest of the cells that were washed and resuspended in 
saline solution. Platelets or the mixed population of platelets 
and leukocytes were spotted on coverslips and incubated for 
90 minutes at 37°C with saturating humidity. The coverslips 
were rinsed with PBS and blocked for 60 minutes with hy-
bridization buffer (0.2% Triton X-100 in PBS plus 1% BSA 
and 2% donkey serum; Sigma, UK); then stained with pri-
mary antibodies against mouse α-tubulin (mouse monoclonal 
antibody, clone B-5-1-2; Sigma, UK, catalogue no. T5168; 
1:200) and COX-1 (rabbit anti-mouse polyclonal IgG; Cell 
Signaling Technology, New England BioLabs, UK; catalogue 
no. 4841S; 1:100) diluted in the same buffer. After washing, 
cells were incubated for 60 minutes with Alexa 488-conju-
gated secondary antibody (donkey anti-mouse polyclonal 
IgG H+L; Life Technologies UK; catalogue no. A-21202; 
1:500) and Alexa 647-conjugated secondary antibody (don-
key anti-rabbit polyclonal IgG H+L; Life Technologies UK; 
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catalogue no. A-31573; 1:500), to detect α-tubulin and COX-
1, respectively, and with DAPI (25 μg/mL; Life Technologies, 
UK) 10 minutes, washed, postfixed, and mounted on slides 
with fluorescent mounting medium (Life Technologies, 
UK). Images were acquired with an oil immersion objective 
(plan-Apochromat 63X/1.4 Oil DIC M27) using an LSM 880 
confocal fluorescence microscope, Axio Observer, equipped 
with four lasers (Diode 405-30/ Argon 458, 488, 514/DPSSS 
561-10/HeNe 633), a Z-piezo stage insert and an Airyscan 
Detector. Immunostaining conditions, laser intensity, and ex-
posure settings were established with minimal/undetectable 
levels of autofluorescence, channel cross talk, and nonspecific 
primary/secondary background fluorescence. Acquisition 
and maximum intensity projection rendering of the images 
was performed with Zen software (version 2.3 SP1, Zeiss, 
Germany). Images were exported to ImageJ (version 1.51a, 
NIH, USA) for final preparation. All images shown in the text 
are representative of at least three independent preparations.
2.5 | Aorta immunostaining
COX-1 expression in the aorta was assessed as previously de-
scribed.37 Mice killed with CO2 were immediately perfused 
across the heart with PBS (20 mL) followed by 5% formalin (20 
mL), and the aorta was carefully removed. The aortic tissue was 
then blocked (20% normal goat serum; Vector Laboratories, 
UK) and permeabilized (0.1% Triton X-100), before being 
treated with primary antibody against mouse COX-1 (rabbit 
anti-mouse polyclonal IgG; Cayman Chemical, USA; catalogue 
no. 160109; 1:50) followed by Alexa 568-conjugated goat anti-
rabbit IgG secondary antibody (Life Technologies, UK; cata-
logue no. A-11036; 1:200). Tissues were counterstained with 
Alexa 488-conjugated anti-CD31 (rat anti-mouse monoclonal 
IgG2a,k; clone MEC13.3; Biolegend, USA; catalogue no. 
102514; 1:100). After staining, aortic rings were cut open to re-
veal the luminal surface, mounted flat between a glass slide and 
coverslip with aqueous hard-set media (Vector Laboratories, 
UK), and pressed until the media had firmly set. The luminal 
surface of aortic rings was visualized with a Leica SP5 inverted 
confocal microscope using a 63× objective oil immersion lens. 
Laser and gain settings were fixed at the beginning of each im-
aging protocol. Nonspecific binding was excluded by subtract-
ing the fluorescence of tissue in which the primary antibody 
was omitted from the staining protocol. Images were exported 
to Image J (version 1.51a, NIH, USA) for final preparation.
2.6 | Enzymatic immunoassay for 6-keto-
PGF1α measurement
Aortic tissue, collected as previously described37 <10 min-
utes after mouse death, was perfused with PBS and dissected 
into small rings (∼2-mm) before being placed into individual 
wells of 96-well microtiter plates (Greiner Bio-one, UK) 
containing DMEM (200 mmol/L L-glutamine; Sigma, UK). 
After 30 minutes of vigorous shaking at 37°C, the media 
were collected and 6-keto-PGF1α measured by ELISA (Enzo 
Life Sciences, USA).
2.7 | Measurement of circulating or 
stimulated total lipid mediators
To stimulate the release of lipid mediators in vitro, blood was 
treated with 50 μmol/L of A23187 (Sigma, UK) or its vehicle 
under stirring conditions in a light transmission aggregom-
eter for 5 minutes. About 100 μmol/L of diclofenac sodium 
(Sigma, UK) and 100 U/mL of heparin (Leo Laboratories, 
UK) were added at the end of the activation process and 
plasma prepared by centrifuging the blood (12000 g, 3 min-
utes, 4°C). Plasma samples were stored at -80°C until lipid-
omic analysis.
For the analysis of the lipid mediators released in vivo, 
mice were anesthetized with ketamine and xylazine (i.p.) 
prior to intravenous (i.v.) injection with vehicle (saline) or 
aspirin (10 mg/kg; Flectadol, Sanofi, Italy). After 10 min-
utes, the synthesis of lipid mediators was stimulated by i.v. 
injection of arachidonic acid (AA; 2.8 mg/kg; Sigma, UK) 
and blood withdrawn from the inferior vena cava into lepi-
rudin 5 minutes later. Some mice were injected with vehicle 
(10% EtOH, 90% saline) rather than AA for measurement of 
the basal circulating levels of products. Plasma samples were 
prepared by centrifuging the blood (12000 g, 3 minutes, 4°C) 
and stored at −80°C until lipidomic analysis.
2.8 | Liquid chromatography tandem mass 
spectrometry analysis of lipid mediators
Lipidomic analysis was performed by liquid chromatog-
raphy tandem mass spectrometry (LC-MS/MS), as previ-
ously described.38,39 Briefly, 250 µL mouse plasma was 
spiked with 30 ng each internal standard, mixed with 1 vol 
of 0.1% acetic acid in 5% methanol containing 0.01 mmol/L 
of butylated hydroxytoluene, and extracted with 3 mL of 
ethyl acetate. Ethyl acetate was passed through Maestro A 
columns (Tecan, Mannedorf, Switzerland) under gravity 
flow into glass tubes containing 6 µL of 30% glycerol in 
methanol. Columns were washed with 1 mL of acetonitrile 
and samples were dried by vacuum centrifugation at 37°C, 
and reconstituted in 30% of ethanol. AA-derived metabo-
lites were then separated by reverse-phase HPLC on a 1 × 
150 mm, 5 μm Luna C18
2 column (Phenomenex, USA) and 
quantified using an MDS Sciex API 3000 triple quadru-
pole mass spectrometer (Applied Biosystems, USA) with 
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negative-mode electrospray ionization and multiple reac-
tion monitoring.
2.9 | Platelet aggregation in whole blood
Platelet aggregation was assessed in whole blood as previ-
ously described.40 Briefly, half-area 96-well microtiter plates 
(Greiner Bio-One, UK) were precoated with hydrogenated 
gelatin (0.75% wt/vol; Sigma, UK) in PBS to block nonspe-
cific activation of blood. AA (0.05-0.5 mmol/L; Sigma, UK) 
or its vehicle were then added to each well, followed by whole 
blood. The plate was then placed onto a heated plate shaker 
(Bioshake IQ, Q Instruments, Germany) at 37°C for 5 min-
utes mixing at 1200 rpm to facilitate platelet aggregation. 
Following mixing, 5 μL of whole blood was removed from 
each well and diluted 1:10 into an acid citrate dextrose so-
lution (5 mmol/L glucose, 6.8 mmol/L trisodium citrate, 3.8 
mmol/L citric acid). In some experiments, blood was preincu-
bated with aspirin (30 μmol/L; Sigma, UK) or its vehicle for 
30 minutes at 37°C. Platelets were labeled with fluorescein 
isothiocyanate (FITC) or allophycocyanin (APC) conjugated 
anti-CD41 (monoclonal rat anti-mouse, clone MWReg30; 
Biolegend, UK; catalogue no. 133913; 1:100) or anti- CD42d-
phycoerythrin (PE) (monoclonal hamster anti-mouse/rat, 
clone 1C2; Biolegend, UK; catalogue no. 148503; 1:100) for 
30 minutes. Samples were then diluted 1:50 in PBS containing 
0.1% of formalin (Sigma, UK), 0.1% of dextrose, and 0.2% 
of BSA before addition of 104 CountBright absolute counting 
beads (Thermo Fisher Scientific, UK). Labeled, diluted blood 
was then analyzed using a FACSCalibur flow cytometer (BD 
Biosciences, Germany) to determine platelet count.
2.10 | FeCl3-induced carotid artery 
thrombosis model
Mice were anesthetized by i.p. injection of ketamine/xylazine 
(100/10 mg/kg body weight). Aspirin (10 mg/kg; Flectadol; 
Sanofi, Italy) or saline were administered i.v. and, after 10 min-
utes, the left common carotid artery was exposed. A miniature 
Doppler flow probe (Transonic) was placed around the artery 
and a 5% FeCl3 (Sigma, UK)-soaked piece of filter paper (1 × 2 
mm) was applied for 3 minutes to induce thrombus formation. 
Blood flow was monitored for 30 minutes and the vessel occlu-
sion time was set as cessation of blood flow for >30 seconds.
2.11 | Principal component analysis and 
hierarchical clustering analysis
Lipid mediator abundance, expressed as ng/mL, was filtered 
to remove those with no signal in any sample. Data were 
normalized against the non-stimulated samples and the data 
set was uploaded to the Partek Genomics Suite (Partek, USA) 
for Principal Component Analysis (PCA). PCA is a multivar-
iate analysis that provides a visual representation of the data 
set with score plots that show the systematic clusters among 
the observations (closer points represent higher similarity in 
the measurements). Data were also uploaded in the Partek 
(v6.6) software to perform hierarchical clustering using a 
Euclidean dissimilarity matrix.
2.12 | Ingenuity pathway analysis
The data set containing eicosanoids identifiers and cor-
responding fold changes and  P values was uploaded onto 
Ingenuity Pathways Analysis (IPA) (01-13) software 
(QIAGEN, USA) and each eicosanoid identifier was mapped 
in the Ingenuity Pathways Knowledge Base (IPKB) to find 
cellular functions and diseases that were significantly asso-
ciated with differentially synthesized eicosanoids. Fisher’s 
exact test was performed to calculate a P value determining 
the probability that each biological function and/or disease 
assigned to the data set was due to chance alone. Downstream 
effect analysis was used to predict changes in diseases and 
functions based on the direction of the change of the meas-
ured eicosanoids. In addition, networks were generated as 
graphical representations of the molecular relationships be-
tween eicosanoids and cellular functions.
2.13 | Statistical analysis
For statistical analysis, GraphPad Prism 8.0 (USA) was used 
to perform t test, one- and two-way ANOVA followed by 
Tukey’s test. P values <.05 were considered statistically 
significant
3 |  RESULTS
3.1 | Characterization of platelet-COX-1-ko 
mice
Platelet-COX-1-ko mice were viable, fertile and demon-
strated a normal Mendelian inheritance ratio. They had nor-
mal platelet, erythrocyte, lymphocyte, and neutrophil counts 
compared to their littermate controls, but slightly decreased 
monocyte counts (Supplemental Table 1). Western blot 
analysis and immunofluorescence staining confirmed the 
absence of COX-1 in platelets (Figure 1A,B). COX-1 was 
still present in leukocytes, aortic endothelial cells (Figure 
1C,D) and homogenates of kidney and lungs (Figure 1E). 
In comparison, COX-1 was not expressed in the blood cells 
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or in other tissues collected from global-COX-1-ko mice 
(Figure 1C,D,F). The effects of platelet COX-1 deletion on 
endothelial function were evaluated by measuring the lev-
els of PGI2, the main COX-1-derived eicosanoid produced 
by the endothelium.37 We first measured the production by 
aortic rings of PGI2, determined as its breakdown product, 
6-keto-PGF1α, and found similar levels in incubates of tissues 
from control (12.91 ± 2.92 ng/mL; n = 3) and platelet-COX-
1-ko (8.92 ± 0.62 ng/mL; n = 3) (P = .66) mice, whereas lev-
els in incubates from global-COX-1-ko mice were reduced 
by more than 95% (0.55 ± 0.01 ng/mL; n = 3) (P = .03 vs 
control mice). Basal circulating levels of 6-keto-PGF1α in 
F I G U R E  1  Characterization of 
platelet COX-1 deletion. A, Control and 
platelet-COX-1-ko platelet lysates were 
subjected to SDS-PAGE and probed for 
COX-1 and GAPDH as indicated. B, Fixed 
and permeabilized platelets from control 
and platelet-COX-1-ko mice were stained 
for tubulin (green) and COX-1 (magenta) 
and imaged with Airyscan laser scanning 
confocal microscopy. Bars represent 2 μm. 
C, The buffy coat was prepared from global-
COX-1-ko, control, and platelet-COX-1-
ko mouse blood with the mixed platelet 
and leukocyte populations being isolated 
prior to staining for tubulin (green), DAPI 
(blue), and COX-1 (magenta) and imaging. 
Bars represent 10 μm. D, Aortas from 
global-COX-1-ko, control, and platelet-
COX-1-ko mice were fixed, permeabilized, 
and stained for COX-1 (magenta) and the 
endothelial marker CD31 (green). Aortas 
were then dissected into rings that were 
cut open to visualize their luminal surface 
by confocal microscopy. Bars represent 
50 μm. E,F, Kidney cortex (Kc), kidney 
medulla (Km), lungs (L), and platelet 
lysates were subjected to SDS-PAGE and 
probed for COX-1 presence. The images are 
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the blood tended to be higher in platelet-COX-1-ko mice 
(339 ± 99 pg/mL, n = 4) and control mice (214 ± 11 pg/mL, 
n = 4) than in global-COX-1-ko mice (60 ± 7 pg/mL, n = 4).
3.2 | Eicosanoid profile of in vitro-
stimulated whole blood and prediction of 
thrombosis-related functions
In vitro stimulation of whole blood with the Ca2+ ionophore, 
A23187, was used to induce receptor-independent activation 
of platelets and leukocytes. Thirty different released lipid 
mediators were detected by LC-MS/MS in blood collected 
from control mice, platelet-COX-1-ko mice and global-COX-
1-ko mice. These data were subjected to PCA and hierarchi-
cal clustering analysis. According to the PCA analysis, lipid 
profiles were distinct for each mouse type; however, platelet-
COX-1-ko and global-COX-1-ko mice were closely associ-
ated (data not shown). In particular, hierarchical clustering 
analysis of the lipid measurements identified three different 
clusters of AA-derived eicosanoids (Figure 2A; red, blue, 
and green outlined boxes), which are shown in further detail 
in Figure 2B (red, blue, and green outlined boxes). In the 
control mice, TxB2, the stable metabolite of TxA2, PGF2α, 
11-HETE, and 15-HETE (cluster in red) were all mark-
edly increased by incubation of whole blood with A23187. 
However, these increases were not observed in blood from 
platelet-COX-1-ko or global-COX-1-ko mice. Together, our 
data shows that the increases in these eicosanoids in whole 
blood result from the activity of platelet COX-1. The pro-
ductions of PGE2 and PGD2 (cluster in blue) in response to 
A23187 were significantly reduced in both platelet-COX-
1-ko and global-COX-1-ko mice, although not abolished, 
meaning that in whole blood the formation of PGE2 and 
PGD2 may also derive from COX-2 activity in other blood 
cells. Syntheses of 12-HETE, 5-HETE, and Leukotriene B4 
(LTB4) (cluster in green), the first a product of 12-lipoxyge-
nase (LOX) activity in platelets and the last two of 5-LOX 
activity in leukocytes, were not affected by either systemic or 
platelet-specific COX-1 deletion.
IPA was used to predict platelet functions and thrombo-
sis-related processes changed on the basis of the measure-
ments of AA COX products synthesized in vitro. Platelet 
activation was predicted as decreased for both platelet-
COX-1-ko and global-COX-1-ko mice compared to control 
mice, and platelet aggregation, morphology, and adhesion 
and carotid artery thrombosis resulted as affected (Figure 
2C). Mainly reduced TxA2 and PGE2 contributed to the 
eicosanoid network supporting these functional predictions 
(Supplemental Figure 1). These data imply that, in vitro, as-
pirin inhibition of COX-1 activity in platelets and in other 
blood cells has similar antithrombotic effects, due to the inhi-
bition of similar eicosanoid networks.
3.3 | Characterization of the profiles of lipid 
mediators released upon administration of AA 
in vivo and predicted influences on thrombosis
Intravenous injection of AA (2.8 mg/kg) to control mice re-
sulted in the generation of 36 distinct metabolites derived 
from AA, linoleic acid (LA), docosahexaenoic acid (DHA), 
and eicosapentaenoic acid (EPA) (Figure 3A provides the 
data for AA COX products; Supplemental Table 2 supplies 
the data for AA non-COX products, as well as LA, DHA, and 
EPA products; Supplemental Table 3 supplies the retention 
time and tandem MS calibrations for AA COX products). As 
well as inducing the production of a variety of lipid media-
tors, the injection of this dose of AA also reportedly induces 
platelet aggregation and thrombosis.41 Distinct profiles of 
AA COX eicosanoids were subsequently established for: (i) 
control mice; (ii) control mice treated with aspirin (10 mg/
kg, i.v.); (iii) platelet-COX-1-ko mice; (iv) platelet-COX-
1-ko mice treated with aspirin; and (v) global-COX-1-ko 
mice. These profiles were not only grouped in different clus-
ters according to both PCA (data not shown) and hierarchi-
cal clustering analysis (Figure 3B); platelet-COX-1-ko mice 
(orange) clustered distinctly from control mice (yellow), 
but also from global-COX-1-ko mice (blue), aspirin-treated 
control mice (green), and aspirin-treated platelet-COX-1-ko 
mice (red), the last three being closely associated.
IPA of the levels of AA COX products released in vivo 
predicted overall protection from thrombosis for platelet-
COX-1-ko mice, but not for aspirin-treated control or glob-
al-COX-1-ko mice. In particular, while the main cellular 
functions regulating platelet reactivity and thrombosis of 
the carotid artery were predicted to be reduced in platelet-
COX-1-ko mice, they were predicted to be increased in both 
aspirin-treated control mice and global-COX-1-ko mice 
(Figure 3C). The eicosanoid networks associated with pre-
dicted reduction in platelet reactivity and thrombosis were 
dominated by dramatically reduced TxA2 and marginal re-
duction of PGE2 in platelet-COX-1-ko mice vs control mice. 
Conversely, decreased production of PGI2, in aspirin-treated 
control mice, and of PGI2 and PGD2, in global-COX-1-ko 
mice, underpinned the predicted increase of platelet reactiv-
ity and thrombosis (Supplemental Figure 2).
These data implied that aspirin’s inhibition of eicosanoids 
other than platelet-derived TxA2 could lead to a detrimen-
tal pro-thrombotic effect of aspirin. To further support these 
findings, we performed additional analyses to predict changes 
in vascular function that could also affect thrombosis. IPA-
predicted arterial relaxation and contraction to be increased and 
decreased, respectively, in platelet-COX-1-ko mice; conversely 
vasodilation and blood flow were predicted to be decreased in 
aspirin-treated control mice or global-COX-1-ko mice, with a 
predicted increase of blood pressure and hypertension which 
predisposes to thrombosis (Supplemental Figure 3).
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Networks of eicosanoids linked to predicted increase of 
vasorelaxation in platelet-COX-1-ko vs control mice simi-
larly featured shifts in TxA2 and PGE2 and additionally mar-
ginal changes in the PGF2α pathway. While reduced synthesis 
of PGI2 was linked to the predicted increase of vascular tone 
and blood pressure in aspirin-treated controls and global-
COX-1-ko mice (Supplemental Figure 4).
3.4 | Validation of the functional 
consequences of selective blockade of platelet 
COX-1 versus whole body actions of aspirin
The IPA predictions of reduced platelet activation in both 
platelet- and global-COX-1-ko mice, based on COX-derived 
eicosanoid networks established upon in vitro whole blood 
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stimulation, were validated using AA-induced platelet aggre-
gation in whole blood. Platelet aggregation was reduced in 
platelets from both platelet-COX-1-ko mice (9% ± 5% ag-
gregation, P = .04) and global-COX-1-ko mice (8.02 ± 8.02, 
P = .06), compared to control mice (62% ± 24% aggregation).
Thrombosis within the carotid artery was used as a model 
to verify the IPA predictions made on the basis of in vivo 
established COX-dependent eicosanoid networks. As pre-
dicted platelet-COX-1-ko mice demonstrated a significantly 
prolonged time for vessel occlusion compared to controls 
(Figure 4), that was normalized by additional treatment with 
aspirin (Figure 4A).
4 |  DISCUSSION
Numerous studies have demonstrated that prophylactic treat-
ment with low-dose aspirin reduces the recurrence of arterial 
thrombotic events.4 However, recent reports have questioned 
the optimal dose of aspirin to use and the true cardiovascular 
benefits of aspirin in combination with other, newer thera-
pies.5-8,11,12 While clinical studies have been put in place to 
answer these questions,7-12 an improved understanding of the 
efficacy of antithrombotic therapies that involve aspirin re-
quires better evaluation of the mechanisms of action of aspi-
rin on platelets and on other targets within the cardiovascular 
system. However, basic research studies addressing the ac-
tions of low-dose aspirin in humans provide limited infor-
mation31,42-44 and studies using mice are hard to translate to 
humans because relatively very high oral aspirin doses are re-
quired to inhibit mouse platelet COX-132,45,46; these elevated 
aspirin levels affect multiple other sites in the body. In the 
present work, we used platelet-COX-1-ko mice to model the 
specific effects of aspirin on platelet COX-1 and to define the 
profile of platelet-derived eicosanoids affected by aspirin. By 
using global-COX-1-ko mice and treating mice with aspirin 
we characterized the profile of eicosanoids affected by lack 
of COX-1 and of COX-1 and COX-2 activity, respectively, 
in the remainder of the body. Finally, we linked the anti- and 
pro-thrombotic effects of aspirin to the eicosanoid networks 
affected and particular platelet and non-platelet-derived ei-
cosanoids (Figure 5).
After confirming the selective deletion of COX-1 in 
platelets and the maintenance of COX-1 at other important 
cardiovascular sites, notably the endothelium, we charac-
terized the production of lipid mediators in whole blood in 
vitro and quantified thirty compounds. Deletion of platelet 
COX-1 was notably associated with marked reductions in 
the production of the eicosanoids TXA2, PGF2α, 11-HETE, 
and 15-HETE. These results not only support the idea that 
inhibition of TxA2 synthesis by platelets is the primary 
mechanism underlying the effect of aspirin in the cardio-
vascular system, but also suggest that additional eicosa-
noids dependent upon platelet COX-1 activity play roles 
in the net antithrombotic action of aspirin. This conclusion 
is consistent with our report that aspirin reduces the pro-
duction of 11-HETE and 15-HETE in whole blood.19 We 
also identified for the first time PGF2α as a platelet-derived 
PG dependent on COX-1 activity. It has been recently sug-
gested that PGF2α acts on EP and TP receptors on plate-
lets and enhances platelet activation,47 which may explain 
some of the effects we observed. Moreover, strong evi-
dence suggests that 15-HETE potentiates platelet aggrega-
tion, decreases PGI2 synthesis in endothelial cells, induces 
vasoconstriction and reduces the inhibitory activity of ni-
tric oxide (NO), while stimulating endothelial and smooth 
muscle cell proliferation and migration.19,48–50 Therefore, 
modulation of COX-1 platelet-derived 15-HETE and 
PGF2α may influence pathologies such as diabetes, myo-
cardial infarction, atherosclerosis, hypertension, or cancer 
and their inhibition by aspirin may underpin some of the 
drug’s beneficial effects.51,52
F I G U R E  2  Tandem mass spectrometry analysis of lipid mediators produced in whole blood and IPA predictions of platelet activation and 
thrombosis. Plasma samples were prepared from mouse blood following incubation in vitro with vehicle or A23187 (50 μM) in stirring conditions 
(1000 rpm, 5 minutes) and subjected to tandem mass spectrometry analysis. A, Relative levels of mediators displayed in a heat map using a Z-score 
ranging from −4.12 (blue) to 4.12 (red). The individual products are represented on the bottom horizontal bar and their clustering on the top, 
while on the left the metabolites are grouped according to stimulated and unstimulated conditions and to the mouse strain. Hierarchical clustering 
analysis identified three different clusters of eicosanoids whose levels are significantly increased upon stimulation of whole blood with A23187 
(50 μM): the cluster including TxB2, PGF2α, 11-HETE, and 15-HETE is indicated in the red box; the cluster including PGE2 and PGD2 is indicated 
in the blue box; and the cluster comprising 12-HETE, 5-HETE, and LTB4 in the green box. B, The absolute plasma levels of these eicosanoids 
as measured by tandem mass spectrometry. Results are from n = 4 global-COX-1-ko, control, and platelet-COX-1-ko mice for each vehicle or 
A23187 treatment and were analyzed by two-way ANOVA followed by Tukey’s test. Data are presented as means ± SEM. *P < .05, **P < .01, 
***P < .001, and ****P < .0001. C, IPA and downstream effects analysis were used to predict the cellular events related to platelet reactivity and 
thrombosis affected by the increase or decrease of AA-derived eicosanoids synthesis by COX in vitro in platelet-COX-1-ko mice and global-COX-
1-ko mice. In the bar charts, the disease and function categories involved in this analysis are displayed along the y-axis. The x-axis displays the 
−(log) significance. Longer bars are more significant than shorter bars. Functions are listed from most significant to least and the vertical dotted 
line denotes the cutoff for significance (P value of .05). Blue and grey indicates diseases or functions that are predicted as decreased or affected, 
respectively.
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Our data also demonstrate that the production of PGE2 
and PGD2 by whole blood are partly dependent upon platelet 
COX-1, with the residual synthesis of these PGs in platelet-
COX-1-ko mice being consistent with production by COX 
enzymes at other cellular sites. In vitro, PGE2 both inhibits 
and potentiates platelet aggregation, depending on its con-
centration and local receptor expression.14 Although PGD2 
has been long regarded as a main macrophage product, Song 
et al have recently demonstrated that platelet activation 
evokes the synthesis of PGD2 and this response is repressed 
in healthy volunteers receiving low-dose aspirin.21 PGD2 in-
teracts with platelet D-type prostanoid receptor 1 (DP1) and 
constrains platelet activation by increasing the activity of 
adenylyl cyclase.20,21 It also restrains thrombosis and athero-
genesis in vivo,21 suggesting that PGD2 inhibition can pro-
duce a pro-thrombotic effect.
A possible limitation of our findings is that the formation 
of PGF2α, PGE2, and PGD2 in platelets might result from the 
nonenzymatic degradation of PGH2. If so in our studies, par-
ticular examination of the respective PG synthetases would 
be required to confirm the production of these metabolites 
by platelets. However, various other studies have pointed to 
a synthetase-dependent metabolism of PGH2 in platelets. For 
instance, blockage of TxA2 synthetase in human platelets 
is associated with an increased synthesis of PGs, including 
PGF2α, PGE2, and PGD2,
53,54 and immunodepletion of lipo-
calin-like PGD synthase suppresses PGD2 formation in plate-
lets stimulated with ADP.21
Overall the combined loss of platelet-derived COX-1 prod-
ucts, TxA2 and PGE2, in the platelet COX-1 mouse was asso-
ciated with a reduction in platelet activation, as suggested by 
IPA and as we verified in platelet aggregation experiments, 
F I G U R E  3  Tandem mass spectrometry analysis of eicosanoids produced in vivo and IPA predictions for platelet reactivity and thrombosis. 
A, Mass spectrometry measurements of COX-derived eicosanoids induced by systemic injection of AA (2.8 mg/kg, i.v.). Data are means ± SEM, 
n = 4-6 mice per group. *P < .05, **P < .01, ***P < .001, and ****P < .0001 (one-way ANOVA followed by Tukey’s post hoc test). B, The 
relative levels of eicosanoids are displayed in a heat map using a Z-score ranging from −4.20 (blue) to 4.20 (red). The individual products are 
identified on the bottom horizontal bar and their clustering on the top, while on the left the clustering of the mice depending on their eicosanoid 
signatures is shown. C, IPA was used to predict changes in processes linked to platelet reactivity and thrombosis based on the determination of in 
vivo eicosanoid synthesis. The bar charts show the most significant changes in platelet-COX-1-ko mice, aspirin-treated control mice, and global-
COX-1-ko mice. Functions are listed from most significant to least. The x-axis displays the -(log) significance and the vertical dotted line denotes 
the cutoff for significance (P value of .05). Blue, red, and grey indicate diseases or functions that are predicted as decreased, increased, or affected, 
respectively.
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consistent with the widely reported antiplatelet effects of as-
pirin. Importantly, the productions in whole blood of the non-
COX-1-dependent products, 5-HETE, 12-HETE, and LTB4 
were unaffected by deletion of platelet COX-1 supporting the 
selectivity of the model.
The effects of platelet COX-1 deletion seen in blood in 
vitro were partially recapitulated in vivo. Notably the produc-
tion of TXA2 was still greatly reduced. However, reductions 
were not seen in the levels of PGE2, PGF2α, 11-HETE, and 
15-HETE indicating that in vivo platelets are at best minor 
contributors to the overall production of these eicosanoids. 
Alternatively, HETE and EET products could have been 
present in the AA injected to stimulate the release of eico-
sanoids in vivo, as a result of the autoxidation of the fatty 
acid (data not shown), which could explain why we did not 
find differences for the in vivo synthesis of 11-HETE and 15-
HETE across the different mouse lines and treatments. Most 
notably, unlike global-COX-ko mice or control mice treated 
with aspirin, platelet-COX-1-ko mice had circulating levels 
of 6keto-PGF1α that were not different from those of control 
mice. This result is consistent with maintenance of endothe-
lial PGI2 production as demonstrated by presence of COX-1 
in endothelial cells and production of PGI2 by isolated aortas, 
and confirms our finding that endothelial COX-1 is a relevant 
source of this potent endogenous inhibitor of platelets and 
thrombosis.34,37
The alterations in eicosanoid profile in platelet-COX-
1-ko mice in vivo were associated by IPA with reduction 
in cardiovascular disease. In particular, the changes in the 
network of eicosanoids driven by reductions in platelet 
COX-1-dependent TxA2 and PGE2 were associated with 
reduced platelet activation and aggregation, and so re-
duced thrombosis of the carotid artery. The networks seen 
in aspirin-treated control mice and global-COX-1-ko mice 
were not associated with an antithrombotic influence, but 
rather with a pro-thrombotic phenotype, consistent with 
reduced synthesis of antithrombotic mediators PGI2 and 
PGD2. The networks for the aspirin-treated control mice 
and global-COX-1-ko mice also indicated greater drives 
toward vasoconstriction than predicted for platelet-COX-1 
mice, consistent with suggestions that TxA2 and PGI2 have 
antagonistic actions on vascular tone; TXA2 being a po-
tent vasoconstrictor and PGI2 a potent vasodilator. Notably, 
vasoconstriction promotes thrombosis.55 These findings 
were further confirmed by IPA predictions of reduced 
synthesis and accumulation of vasorelaxant mediators and 
signaling molecules, including cyclic adenosine mono-
phosphate, NO, and cyclic guanosine monophosphate in 
aspirin-treated control mice (data not shown). In particular, 
reduced synthesis and signals of NO could be related to 
increased levels of asymmetric dimethylarginine (ADMA), 
an endogenous inhibitor of endothelial NO synthase, that 
could have been caused by COX-2 inhibition by aspirin. In 
fact, some of our group have recently reported that lack of 
COX-2 in mice or treatment with a COX-2 selective inhib-
itor leads to increased levels of ADMA in the plasma.56,57
Finally, to validate IPA predictions derived by the mea-
surement of AA COX products in vivo, we compared the 
effects of loss of COX-1 activity in platelets and the effects 
of aspirin on non-platelet targets in a model of in vivo throm-
bosis. As predicted, platelet-COX-1-ko mice had an anti-
thrombotic phenotype compared to control mice. Similarly, 
as predicted, addition of aspirin to platelet-COX-1-ko mice 
F I G U R E  4  In vivo thrombosis. A, In vivo thrombus formation 
was studied in the carotid artery in response to exposure to 5% FeCl3 
for 3 minutes. The time to occlusion was quantified in control mice 
and platelet-COX-1-ko mice under control conditions or following 
treatment with aspirin (10 mg/kg, i.v.). The data are means ± SEM, 
n = 6-8 mice per group. *P < .05 (one-way ANOVA followed by 
Tukey’s post hoc test). B, Traces of blood flow rate in carotid arteries 
during thrombosis model in (blue line) control mice and (red line) 
platelet-COX-1-ko mice
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reduced the time to reach vascular occlusion indicating an in-
crease in thrombosis. For this study, we used acute i.v. injec-
tion of a single dose of aspirin (10 mg/kg) which can reduce 
both COX-1 and COX-2 activity. However, we conclude that 
the pro-thrombotic effect of aspirin we observed is explained 
by inhibition of COX-1 rather than COX-2. This conclusion 
is supported by our recent report that acute COX-2 inhibi-
tion does not affect thrombosis but that selective deletion of 
COX-1 from endothelial cells is pro-thrombotic, with this 
latter effect overcome when COX-1 is deleted from both en-
dothelial cells and platelets.34 We have previously shown that 
i.v. doses of aspirin lower than the one used for the present 
study have non-platelet effects,58 therefore, we did not ex-
plore the effect of escalating doses of aspirin on lipid media-
tor formation and thrombosis.
In conclusion, our results demonstrate that the cardio-
vascular actions of aspirin mediated through inhibition of 
platelet COX-1 or of extra-platelet aspirin targets can be ex-
plained by profiling in vitro and in vivo eicosanoid forma-
tion. These in vitro and in vivo profiles definitively show that 
while in vitro aspirin mimics the effect of specific platelet 
COX-1 inhibition, in vivo aspirin has additional non-plate-
let effects on eicosanoid formation that promote thrombosis. 
Our study suggests a mechanistic explanation for the main 
findings of recent trials showing no additive antithrombotic 
effect of aspirin when in combination with P2Y12 receptor 
antagonists.11,12 In agreement with previous reports,59,60 this 
study also shows the potential of combining comprehensive 
lipidomic analysis with platelet function analysis to assess 
the effectiveness of antithrombotic treatments and establish 
the potential for individualized antithrombotic drug regimes. 
The responses of an individual to aspirin are a net response 
resulting from the state of the platelet and the networks of 
eicosanoids being produced at platelet and non-platelet sites.
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